Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review.
-
アブストラクト The role for PD-1/PD-L1 and CTLA-4 targeted immunotherapy is well outlined in the treatment of metastatic NSCLC. Increased survival benefit supports the use of these medications and the development of next-generation agents with improved efficacy and favorable side-effect profiles. The prevalence of immunotherapy-associated cardiotoxicity (IAC) has grown significantly over the past two years as awareness of this toxicity class has emerged. High-grade conduction disorders comprise a subset of cardiotoxicities with a high case fatality rate. We presented a case of suspected combination ipilimumab-nivolumab associated 3rd degree heart block. The onset of this event was 16 days after immunotherapy initiation. A literature review has suggested that over 75% of cases of cardiotoxicity are observed within the first 6 weeks. We present findings from an interrogation of the FDA Adverse Event Reporting System (FAERS) and provide clinical guidance for the early identification of high-risk patients. ジャーナル名 Respiratory medicine case reports Pubmed追加日 2021/4/1 投稿者 Vartanov, Alexander; Kalotra, Aditi; Varughese, Jasmine; Gautam, Shovendra; Kandel, Sean; Hosmer, Wylie 組織名 Department of Medicine, University of Connecticut School of Medicine, 263;Farmington Avenue L2104, Farmington, CT, 06030, USA.;Department of Medicine, Hospital of Central Connecticut, 100 Grand Street, New;Britain, CT, 06052, USA.;Department of Medical Oncology, Hartford Healthcare, 201 North Mountain Road;Suite 202, Plainville, CT, 06062, USA. Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/33786301/ -
お問合わせ
検索
メルマガ登録
